MIRA_OUT_1 [2025-04-16 09:30:08 -0400] 4225 Bytes | 1078 tokens | Cum: 1078 tkns (13.48% of 8k)
==========================================================================

We're scouting for winners today. Its 9:30:07 AM on Wed Apr 16, 2025 -0400 and I'm looking at MIRA Pharmaceuticals (MIRA) up to 1.2900 from 0.8972

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: MIRA Pharmaceuticals (MIRA)
IPO: 2023-08-03 (1 Year Ago)
Market Cap: $14,858,396
Shares Outstanding: 16,810,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Here’s a list of headlines for MIRA Pharmaceuticals:

Today 08:00AM - MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
07:15AM - EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
Apr-02-25 08:37AM - Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2
Apr-01-25 08:00AM - MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
Mar-25-25 09:00AM - Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit
Mar-24-25 07:30AM - MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
Mar-24-25 07:30AM 07:16AM - EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
Mar-14-25 11:40AM - Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-02-06T10:00:00Z - Kernel and Mira Launch Industry’s First $300M Secured AI API
B2 - 2024-03-27T12:14:28Z - Why MariaDB Shares Are Trading Higher By Around 100%; Here Are 20 Stocks Moving Premarket
B3 - 2024-03-08T18:47:01Z - Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
B4 - 2024-03-08T13:23:50Z - Why Porch Group Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
B5 - 2024-02-05T17:56:50Z - Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
B6 - 2023-11-27T18:41:21Z - Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for MIRA Pharmaceuticals (MIRA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

MIRA_OUT_3 [2025-04-16 09:30:09 -0400] 1039 Bytes | 299 tokens | Cum: 1379 tkns (17.24% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-16T12:07:22Z - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Adaptive Biotechnologies (NASDAQ:AD...
A2 - 2025-04-16T12:02:00Z - MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, R...
A3 - 2025-04-16T11:15:58Z - EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Anim...
A4 - 2025-04-16T11:31:14Z - EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Anim...
A5 - 2025-04-01T12:14:00Z - MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic P...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MIRA_OUT_5 [2025-04-16 09:30:10 -0400] 1181 Bytes | 341 tokens | Cum: 1722 tkns (21.52% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Adaptive Biotechnologies (NASDAQ:ADPT), Aptorum Gr (NASDAQ:APM)**Date: 2025-04-16Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44835988/12-health-care-stocks-moving-in-wednesdays-pre-market-sessionGainers icad ICAD shares increased by 72.0% to $3.32 during Wednesday's pre-market session. The company's market cap stands at $87.4 million. Universe Pharmaceuticals UPC stock increased by 17.82% to $3.9. The market value of their outstanding shares is at $59.3 million. Renovaro RENB stock rose 12.39% to $0.42. The market value of their outstanding shares is at $66.6 million. Assembly Biosciences ASMB shares increased by 10.09% to $10.8. The market value of their outstanding shares is at $81.0 million. Mira Pharmaceuticals MIRA shares moved upward

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_7 [2025-04-16 09:30:11 -0400] 1181 Bytes | 350 tokens | Cum: 2074 tkns (25.92% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): s by 9.06% to $0.98. The company's market cap stands at $16.2 million. China SXT Pharmaceuticals SXTC stock rose 8.81% to $1.85. The company's market cap stands at $25.4 million. Losers Forian FORA stock declined by 61.1% to $0.81 during Wednesday's pre-market session. The company's market cap stands at $25.2 million. BioCardia BCDA shares declined by 15.13% to $1.74. The company's market cap stands at $7.9 million. Syra Health SYRA stock decreased by 14.56% to $0.17. The market value of their outstanding shares is at $2.0 million. Adaptive Biotechnologies ADPT stock fell 13.44% to $6.7. The company's market cap stands at $988.7 million. Century Therapeutics IPSC stock decreased by 11.18% to $0.45. The market value of their outstanding shares is at $38.2 million. Aptorum Gr APM shares declined by 11.03% to $0.96. The market value of their outstanding shares is at $6.8 million. See Also:

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_9 [2025-04-16 09:30:12 -0400] 1102 Bytes | 359 tokens | Cum: 2435 tkns (30.44% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPTAdaptive Biotechnologies Corp$6.70-13.4%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum98.38Growth-Quality-Value31.01Price TrendShortMediumLongOverviewAPMAptorum Group Ltd$0.9645-10.7%ASMBAssembly Biosciences Inc$10.406.01%BCDABioCardia Inc$1.74-15.1%FORAForian Inc$0.8000-61.6%ICADicad Inc$3.2970.2%IPSCCentury Therapeutics Inc$0.4450-11.2%MIRAMira Pharmaceuticals Inc$0.94004.77%RENBRenovaro Inc$0.38192.22%SXTCChina SXT Pharmaceuticals Inc$1.710.59%SYRASyra Health Corp$0.1840-10.2%UPCUniverse Pharmaceuticals Inc$3.15-4.84%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_11 [2025-04-16 09:30:13 -0400] 807 Bytes | 204 tokens | Cum: 2641 tkns (33.01% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-28 10-K MGT DISC & ANALYSIS OF

FIN COND & RESULTS OF OPER

The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our results of operations and financial condition. Y...

S2 - 2025-03-24 8-K Item 1.01 Entry into a Material Definitive Agrmt

On March 19, 2025, MIRA Pharmaceuticals, Inc. (the Company) entered into a binding letter of intent (the LOI) with SKNY Pharmaceuticals, Inc. (SKNY), a privately held Delaware corporation, to acquire SKNY through a stock exch...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MIRA_OUT_13 [2025-04-16 09:30:15 -0400] 1181 Bytes | 230 tokens | Cum: 2873 tkns (35.91% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
MANAGEMENTS DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of our results of operations and financial condition. You should read the following discussion and analysis of our results of operations and financial condition together with our financial statements and related notes and other information included elsewhere in this Report.

In addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of various factors, including those set forth under Risk Factors and Cautionary Note Regarding Forward-Looking Statements includ

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_15 [2025-04-16 09:30:16 -0400] 1181 Bytes | 269 tokens | Cum: 3144 tkns (39.30% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ed elsewhere in this Report. Additionally, our historical results are not necessarily indicative of the results that may be expected for any period in the future.

Overview

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company advancing two neuroscience programs targeting neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function.

The U.S. Drug Enforcement Administration (DEA)s scientific review of Ketamir-2 and MIRA-55 concluded that it would not be considered a controlled substance or listed chemical under the Controlled Substances Act (CSA) and its governing regulations.

We had net losses of $7.9 million and $12.0 million for the year

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_17 [2025-04-16 09:30:19 -0400] 1181 Bytes | 256 tokens | Cum: 3402 tkns (42.52% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): ended December 31, 2024 and December 31, 2023, respectively.

Reverse Stock Split

Effective June 28, 2023, we completed a 1-for-5 reverse stock split of our outstanding common stock. Unless otherwise noted, the share and per share information in this Report reflects the reverse stock split.

##TABLE_START 58 ##TABLE_END

##TABLE_START ##TABLE_END

Components of our Results of Operations

Research and Development Expenses

Research and development expenses represent costs incurred to conduct research and development of our product candidate. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:

##TABLE_START contracted research and manufacturing; patent-related costs; consulting arrangements; and other expenses incurred to advance our research and development activities. ##TABLE_END

Our operati

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_19 [2025-04-16 09:30:22 -0400] 1181 Bytes | 234 tokens | Cum: 3638 tkns (45.48% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ng expenses have historically been the costs associated with our patent prosecution and initial investment in pre-clinical research and development activities. We expect research and development expenses will increase in the future as we advance Ketamir-2 and MIRA-55 into and through clinical trials and pursue regulatory approvals, which will require a significant investment in costs of clinical trials, regulatory support, and contract manufacturing. In addition, we will evaluate opportunities to acquire or in-license additional product candidates and technologies, which may result in higher research and development expenses due to license fee and/or milestone payments, as well as added clinical development costs.

The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely development and achieving regul

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_21 [2025-04-16 09:30:23 -0400] 1181 Bytes | 235 tokens | Cum: 3875 tkns (48.44% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): atory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates.

General and Administrative Expenses

General and administrative expenses consist of employee-related expenses, including salaries, benefits, and travel, and other administrative functions, as well as fees paid for legal, accounting and tax services, consulting fees and facilities costs not otherwise included in research and development expense. Legal costs include general corporate legal fees. We expect to incur additional expenses as a result of becomin

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_23 [2025-04-16 09:30:24 -0400] 790 Bytes | 186 tokens | Cum: 4063 tkns (50.79% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): g a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq, additional insurance, investor relations and other administrative expenses and professional services.

Interest expense

Interest expense, net consists of accrued interest on a related party line of credit, net of earned interest income.

##TABLE_START 59 ##TABLE_END

##TABLE_START ##TABLE_END

Results of Operations for the year ended December 31, 2024 and 2023

##TABLE_START Year E...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

MIRA_OUT_25 [2025-04-16 09:30:38 -0400] 5776 Bytes | 1482 tokens | Cum: 5547 tkns (69.34% of 8k)
==========================================================================

This is our set of metrics for MIRA Pharmaceuticals.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+-----------------------+
| Volume: 57,266 | Perf Month: -16.93% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 253.70K | Perf Quarter: -23.32% | Short Float: 4.61% | ROE: -238.90% |
+---------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.22 | Index: - | Short Ratio: 2.27 | ROI: -356.98% |
+---------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 41.27 | Market Cap: 15.08M | Short Interest: 0.57M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.08 | Shs Outstand: 16.56M | Beta: 2.10 | EPS Surprise: -30.56% |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA20: -10.51% | Shs Float: 12.48M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA50: -14.68% | Inst Own: 6.66% | Sales past 5Y: 0.00% | Earnings: Feb 26 |
+---------------------+-----------------------+------------------------+-----------------------+
| SMA200: -32.09% | Insider Own: 25.79% | Employees: 5 | |
+---------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 8.10% | Insider Trans: -2.25% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by MIRA Pharmaceuticals officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -7852659.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.29
Average Volume: 1133675.65
30-Day High: 1.29
30-Day Low: 0.8028

[Detailed Financials: TTM 2024]
- Total Assets: $2,923,099.0
- Total Liabilities: $723,349
- Total Equity: $2,199,750.0
- Current Assets: $2,887,660.0
- Current Liabilities: $723,349

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.51

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0

[Detailed Financials: FY 2024]
- Total Assets: $2,923,099.0
- Total Liabilities: $723,349
- Total Equity: $2,199,750.0
- Current Assets: $2,887,660.0
- Current Liabilities: $723,349

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.51

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of MIRA Pharmaceuticals (MIRA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about MIRA Pharmaceuticals.

2) MARKET_SCORE[]
This conversation was initiated because MIRA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for MIRA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, MIRA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect MIRA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of MIRA Pharmaceuticals.

11) ETHICAL_RATING[]
Rate MIRA Pharmaceuticals’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of MIRA Pharmaceuticals.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

MIRA_IN_27 [2025-04-16 09:30:39 -0400] 126 Bytes | 29 tokens | Cum: 5790 tkns (72.38% of 8k)
==========================================================================

====================================
[2025-04-16 09:30:39] # Analysis Completed
Elapsed Time: 32.19 seconds